Can virus-like particles unleash a new wave of CRISPR treatments?; Fosun Pharma and Insilico team up in AI discovery deal
The biggest challenges in genome editing today have a lot less to do with how to build tools that can cut, paste or rewrite DNA and a lot more to do with how to get the tools we have to the right parts of the body.
One method is to employ the viral vectors commonly used in gene therapy, but CRISPR-Cas9 systems are often too large and cumbersome to fit inside these viruses, which also come with their own safety issues. Viral vectors also leave the genome-editing tool permanently expressed inside cells, even after it’s made the required edit, potentially leading to unwanted changes and other types of cell damage.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters